Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute, shared on X/Twitter:

“Pleased to share our ARCHES analysis of efficacy, safety, and quality of life of enzalutamide (ENZA)/androgen-deprivation therapy (ADT) in men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by age (>75 vs <75) in the European Urology Oncology journal.”

For the article, click here.
Source: Andrew Armstrong/X